Research programme: cyclin dependent kinase inhibitors - G1 Therapeutics

Drug Profile

Research programme: cyclin dependent kinase inhibitors - G1 Therapeutics

Alternative Names: Chemoprotection therapies - G1 Therapeutics; G1T-48; Pharmacoquiescence (PQ™); Radioprotection therapies - G1 Therapeutics

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G1 Therapeutics
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 09 Aug 2017 G1 Therapeutics announces intention to submit IND for ER-positive HER2-negative Breast cancer in the fourth quarter of 2017
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 10 Jan 2017 G1 Therapeutics plans a phase I trial for Breast cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top